// App-Quantinova.ai

SU-OR34 : Belimumab (BEL) Improves Renal Outcomes in Active Lupus Nephritis (LN): A Phase 3 Randomized, Placebo (PBO)-Controlled Trial

Researchers

Presenter

  • Rovin BradH

Principal Investigators

  • Houssiau Frederic

  • Furie Richard

  • Malvar Ana

  • Teng Yoe Kie Onno

  • Mok Chi chiu

  • Contreras Gabriel

  • Yu Xueqing

  • Dolff Sebastian

  • Ji Beulah

  • Roth DavidA

  • Kleoudis Christi

  • Makowiak Susan

  • Madan Anuradha

  • Gilbride Jennifer

  • Green Yulia

Medical Centers

  • Division of Nephrology, Ohio State University, Columbus, United States

  • Pole de pathologies rhumatismales, Institut de Recherche Experimentale et Clinique, Universite catholique de Louvain and Service de Rhumatologie, Cliniques Universitaires Saint-Luc, Brussels, Belgium

  • Division of Rheumatology Northwell Health Great Neck New York United States

  • Organizacion Medica de Investigacion, Buenos Aires, Argentina

  • Expert Center for Lupus- Vasculitis- and Complement-mediated Systemic diseases Department of Internal Medicine – section Nephrology Leiden University Medical Center Leiden Netherlands

  • Tuen Mun Hospital Department of Medicine and Geriatrics Hong Kong Hong Kong

  • Division of Nephrology Division of Hypertension Department of Medicine University of Miami Miller School of Medicine Miami Florida United States

  • Department of Hematology, Guangdong nd People Hospital, Guangzhou, China

  • Department of Infectious Diseases, University Hospital Essen, University of Duisburg‐Essen,

  • GlaxoSmithKline, Uxbridge, United Kingdom

  • GSK, Collegeville, Pennsylvania, United States

  • Parexel Durham North Carolina United States

  • GlaxoSmithKline, Stevenage, United Kingdom.

Locations

  • United States

  • Belgium

  • Argentina

  • Netherlands

  • China

  • Germany

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Microvascular complications of diabetes 1

  • Lupus nephritis

  • Renal disease

  • Albuminuria

  • Nephritis

  • Lupus

Biomarkers

  • Creatinine

Drug/Treatment

  • Mycophenolate mofetil

  • CKD-4101

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • Mycophenolic acid

  • Oraprine

  • Belimumab

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Controlled

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved